Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

A low PEG ratio hints at value, but does it guarantee a great investment? Some stocks justify their price, others are cheap ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back HalfExploring Strategic Options for Personal Care ...

Palantir's growth is of extremely high quality, showcasing accelerating growth. Click here to read why I keep a Hold rating ...

Q4 2024 Earnings Call Transcript February 6, 2025 ITT Inc. beats earnings expectations. Reported EPS is $1.5, expectations ...

With cyber threats on the rise, the cloud security market is growing rapidly. Investors looking to capitalize on this trend ...

Disney reported a double beat with better-than-expected Q1 results, despite a decline in Disney+ subscriptions. Check out why ...

Net revenues of Euro 6,677 million, up 11.8% versus prior year, with total shipments of 13,752 unitsOperating profit (EBIT)(1) of Euro 1,888 ...

Coca-Cola (KO) will likely continue delivering mid-single-digit organic revenue growth this year and outperforming peers despite a challenging earnings backdrop, UBS Securities said Monday. While Coca ...

The Indian stock market is crashing, yet some stocks defy gravity with sky-high P/E ratios. Are they future growth bets or ...

Church & Dwight Co., Inc. (NYSE: CHD) today announced the Company exceeded its outlook with stronger than expected sales growth. Full year 2024 net sales increased 4.1% to $6,107.1 million, ahead of ...